MedTrace Logo

Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)

NCT04870164 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2022-03-18

No results posted yet for this study

Summary

This study will investigate how ensovibep is distributed throughout the body, the safety and the tolerability of ensovibep in healthy volunteers

Conditions

Interventions

DRUG

Ensovibep

The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohorts. 3 IV infusion, 2 IV bolus, 4 subcutaneous and 4 intramuscular cohorts are planned. Subjects receive one or two administration(s) on day 1, depending on the cohort.

DRUG

Placebo

One administration at day 1 by infusion.

Sponsors & Collaborators

  • Molecular Partners AG

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2022-01-06
Completion
2022-01-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04870164 on ClinicalTrials.gov